Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2011 articles with Gilead Sciences, Inc.
-
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
5/19/2022
Gilead Sciences, Inc. was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS.
-
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
5/17/2022
Gilead Sciences, Inc. and Kite, a Gilead Company, announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be presented at the 2022 American Society of Clinical Oncology Annual Meeting.
-
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
5/16/2022
Gilead Sciences, Inc. announced the U.S. Food and Drug Administration has lifted the clinical hold placed on the company’s Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis.
-
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
5/2/2022
Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications.
-
Gilead and Dragonfly announced their collaboration today, with an end goal of bringing the DF7001 NK engager program designed for patients with cancer or inflammatory diseases.
-
Gilead’s Veklury made massive profits, but as more vaccine boosters arrive and more people become immune to the virus, the future of the antiviral is in question.
-
Gilead Sciences Announces First Quarter 2022 Financial Results
4/28/2022
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2022.
-
Weeks after Gilead Sciences raised concern over counterfeit HIV drugs, Johnson & Johnson has taken similar action against the distribution of counterfeit prescription drugs.
-
Gilead Sciences to Present at Upcoming Investor Conferences - Apr 26, 2022
4/26/2022
Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conferences.
-
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
4/25/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of pediatric patients who are older than 28 days, weighing at least 3 kg, and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe COVID-19, including hospitalization or death.
-
The FDA has now approved the first treatment for COVID-19 in young children, expanding its approval for Gilead's Veklury to children who are at least 28 days old and weigh at least three kilograms.
-
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
4/24/2022
Gilead Sciences, Inc. announced findings from two studies, which provide further insights on the use of Veklury® for the treatment of hospitalized and non-hospitalized patients with COVID-19.
-
Toxicities and concerning patient survival data sparked a U.S. Food and Drug Administration advisory committee to recommend shutting the door on single-arm clinical studies of PI3K inhibitors.
-
Gilead Sciences scored a legal victory regarding fraudulent HIV reimbursements, securing a court order against a number of clinics, labs and prescribers in Florida that were engaging in the alleged fraud.
-
The U.S. FDA's Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
4/14/2022
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2022 financial results will be released on Thursday, April 28, after the market closes.
-
The FDA's decision to lift the hold directive on April 11 involving the investigational drug magrolimab follows a comprehensive review of each trial's safety data.
-
Veru posted positive interim Phase III data from its late-stage study assessing oral antiviral sabizabulin in hospitalized COVID-19 patients. Here's more about it.
-
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
4/11/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination with azacitidine.